Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma
- First Posted Date
- 2015-06-17
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 171
- Registration Number
- NCT02474563
Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 10
- Registration Number
- NCT02472392
- Locations
- 🇺🇸
University of Louisville, Louisville, Kentucky, United States
Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2016-07-12
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT02447055
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- Procedure: Autologous Bone Marrow TransplantationProcedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarmustineDrug: CyclophosphamideDrug: CytarabineDrug: EtoposideDrug: IbrutinibOther: Laboratory Biomarker AnalysisDrug: MelphalanOther: Placebo AdministrationOther: Pharmacogenomic Study
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 302
- Registration Number
- NCT02443077
- Locations
- 🇺🇸
Logan Health Medical Center, Kalispell, Montana, United States
🇺🇸Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2023-01-04
- Target Recruit Count
- 57
- Registration Number
- NCT02440464
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Texas /MD Anderson CRC, Houston, Texas, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 29
- Registration Number
- NCT02435901
- Locations
- 🇺🇸
Cohen Children's Medical Center of New York, New Hyde Park, New York, United States
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 90
- Registration Number
- NCT02415413
- Locations
- 🇪🇸
Hospital Clínico San Carlos, Madrid, Spain
🇪🇸Hospital Clínic de Barcelona, Barcelona, Spain
🇪🇸Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Delcath Systems Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT02415036
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪Universitätsklinikum Jena, Jena, Germany
🇩🇪Universitätsklinikum Frankfurt, Frankfurt, Germany
A Pharmacokinetic Study of Melphalan in Children
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 34
- Registration Number
- NCT02390544
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
- Conditions
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT02366663
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.